• There are several AP binding sites in the sequence of

  2024-07-10

  

  There are several AP-1 rolipram mg in the sequence of TIMP-1 promoter [18,19]. EBV could up-regulate TIMP-1 expression by binding to the AP-1 site in the TIMP-1 promoter [18]. IL-32, a newly multi-function cytokine, could activate AP-1, NF-κβ, p38MAPK signal pathways, and induce cytokine expression

• Most human diseases e g

  2024-07-10

  

  Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te

• Studies have demonstrated that AT plays a

  2024-07-09

  

  Studies have demonstrated that AT2 plays a greater role in modulating arterial pressure in females than in males. Chronic low-dose infusion of Ang II decreased blood pressure in female rats at a dose that had negligible effects in males. Furthermore, AT2 blockade eliminates the depressor response to

• Given that the FST protocol for

  2024-07-09

  

  Given that the FST protocol for mice does not engage the exposure to a previous stressful session, posits that Agtr1a levels could be kept higher by basal glutamatergic transmission rather than by stressful stimuli as postulated before. To address this possibility, we used the EMBL-EBI Expression At

• br Prostate cancer and resistance to AR targeting treatment

  2024-07-09

  

  Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an

• Similar studies in Swedish Mutation of APP AD transgenic mic

  2024-07-09

  

  Similar studies in Swedish Mutation of APP AD transgenic mice revealed reduced dynamin 1, AP180, and synaptophysin expression in the hippocampus, particularly prominent in the CA1 and CA4 subfields [19]. These findings imply that Aβ can act not only as a modulator of exocytosis but is a potent regul

• Another possible scenario is that

  2024-07-09

  

  Another possible scenario is that the same pathologic process has different effects in different people. It might be that the pathway outlined in Fig. 6A is operative in some individuals, but other individuals have a factor Q (which could be genetic or environmental) that blocks the effect of A on T

• The decreased AR mediated response

  2024-07-09

  

  The decreased βAR-mediated response has been attributed to different mechanisms, including an attenuation of PKA activation, an impaired generation of cyclic AMP, a reduced receptor density, and a less efficient coupling to adenylyl-cyclase [10]. However, currently there is no single molecular or ce

• Oxytocin receptor The study by Lo http www apexbt com

  2024-07-09

  

  The study by Lowry et al. (2001) pointed toward functionally uncharacterized DA- and 5-HT-accumulating neurons within the DMH as a potential target for rapid nongenomic effects of CORT. Similar DA- and 5-HT-accumulating systems are distributed throughout the central and peripheral nervous systems, s

• Mechanisms implicated in antinociception by A R

  2024-07-09

  

  Mechanisms implicated in antinociception by A3R agonists in neuropathic pain are summarized in Box 3. Cellular transduction mechanisms for A3Rs include inhibition of cyclic AMP, PKA via Gαi, interactions with PLC/IP3/DAG and signaling via Gαi and Gαq, and interactions with PI3K/MEK/ERK via βγ subuni

• Although ACE genetic variance does not influence the level

  2024-07-09

  

  Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to

• br LOX in colorectal cancer Colorectal

  2024-07-09

  

  5-LOX in colorectal cancer Colorectal cancer (CRC) like other malignancies exhibits an overexpression of 5-LOX. Ohd et al. (Ohd et al., 2003) revealed in a study that malignant colon tissues overexpress 5-LOX activity and retain elevated levels of inflammatory mediators, leukotrienes. Additionall

• br Materials and methods br Results br

  2024-07-09

  

  Materials and methods Results Discussion The success of CAR-T cell therapy is based on two major facts: one is that cancer cells express tumor-associated antigens (TAAs) on their surface that can be detected by the human immune system; the other is that the CAR molecules target these TAAs o

• Aurora A or B selective and

  2024-07-09

  

  Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas

• ATM is required for the proper

  2024-07-08

  

  ATM is required for the proper function of the DNA-repair pathway in response to bleomycin-induced DNA damage in mammalian cells [55], [56]. Recent reports suggest that ATM activation by double-strand breaks leads to the subsequent ATR activation [57], [58], [59]. The recruitment of ATR to double-st

16663 records 125/1111 page Previous Next First page 上5页 121122123124125 下5页 Last page